1. Home >
  2. M&A >
  3. Divestiture >
  4. United States >
  5. California >
  6. Zenas BioPharma Acquires Obexelimab

M&A Deal Summary

Zenas BioPharma Acquires Obexelimab

On November 11, 2021, Zenas BioPharma acquired life science company Obexelimab from Xencor

Acquisition Highlights
  • This is Zenas BioPharma’s 1st transaction in the Life Science sector.
  • This is Zenas BioPharma’s 1st transaction in the United States.
  • This is Zenas BioPharma’s 1st transaction in California.

M&A Deal Summary
Date 2021-11-11
Target Obexelimab
Sector Life Science
Buyer(s) Zenas BioPharma
Sellers(s) Xencor
Deal Type Divestiture

Target

Obexelimab

Monrovia, California, United States
Obexelimab is a potential first-in-class bifunctional antibody that targets CD19 with its variable domain and uses Xencor’s XmAb®Immune Inhibitor Fc Domain to target FcγRIIb, a receptor that inhibits the function of B-cells, which are important components in the immune system. Obexelimab is based in Monrovia, California.

Search 214,239 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

Zenas BioPharma

Waltham, Massachusetts, United States
Category Company
Founded 2019
Sector Life Science
Employees130
Revenue 5M USD (2024)
DESCRIPTION

Zenas BioPharma is a global biopharmaceutical company develops and delivery of immune-based therapies for patients in the US, China and around the world. Zenas BioPharma was founded in 2019 and is based in Waltham, Massachusetts.

DEAL STATS #
Overall 1 of 1
Sector: Life Science M&A 1 of 1
Type: Divestiture M&A Deals 1 of 1
State: California M&A 1 of 1
Country: United States M&A 1 of 1
Year: 2021 M&A 1 of 1

Seller(S) 1

SELLER

Xencor

Pasadena, California, United States
Category Company
Founded 1997
Sector Life Science
Employees250
Revenue 110M USD (2024)
DESCRIPTION

Xencor is a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases. Currently, 22 candidates engineered with Xencor's XmAb® technology are in clinical development internally and with partners. Xencor was founded in 1997 and is based in Pasadena, California.

DEAL STATS #
Overall 1 of 1
Sector: Life Science M&A 1 of 1
Type: Divestiture M&A Deals 1 of 1
State: California M&A 1 of 1
Country: United States M&A 1 of 1
Year: 2021 M&A 1 of 1
Mergr

Solution for

Product

Company

Legal